<h4>Background</h4>Studies comparing treatment strategies based on initiation timing-such as starting PCSK9 inhibitor (PCSK9i) therapy sooner versus later after a myocardial infarction (MI)-are prone to immortal time bias. This evidence concerns the gene PCSK9 and myocardial infarction.